Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 27,757 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo and sham treatment Clear all
Completed Phase 2 Interventional Results available

Study of Elobixibat (A3309) in Patients With Chronic Idiopathic Constipation

NCT01007123
View directory record Official record
Conditions
Constipation, Chronic Constipation
Interventions
A3309
Drug
Lead sponsor
Albireo
Industry
Eligibility
20 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
44
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of the Effect of Low Level Laser Light Therapy on Reducing the Appearance of Cellulite in the Thighs and Buttocks.

NCT01702259
View directory record Official record
Conditions
Cellulite
Interventions
Erchonia Scanner device (GLS), Placebo device
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
2
States / cities
Marion, Indiana • Bloomfield Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis

NCT03313180
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Propranolol on Preventing Posttraumatic Stress Disorder

NCT00158262
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Propranolol, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 15, 2026, 9:03 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder

NCT06115603
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Cannabigerol, Placebo
Drug · Other
Lead sponsor
University of Arkansas, Fayetteville
Other
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

NCT01205503
View directory record Official record
Conditions
Breast Cancer, Non-Hodgkin's Lymphoma
Interventions
Mesna, Saline, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Mara Chambers
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy and Safety Evaluation of Anti-Caries Varnish

NCT04947527
View directory record Official record
Conditions
Dental Caries in Children
Interventions
Test varnish, Placebo
Drug
Lead sponsor
Advantage Silver Dental Arrest, LLC
Industry
Eligibility
10 Months to 20 Months
Enrollment
274 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Effects of a Novel Dietary Microalgae Based Ingredient on Muscle Recovery and Endurance Capacity

NCT05760742
View directory record Official record
Conditions
Healthy
Interventions
MicAlgae, Placebo
Dietary Supplement
Lead sponsor
Microphyt
Industry
Eligibility
18 Years to 35 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily

NCT00827242
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Placebo, tadalafil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Huntsville, Alabama • Middlebury, Connecticut • Sarasota, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2010 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI

NCT00067470
View directory record Official record
Conditions
Mucopolysaccharidosis VI
Interventions
Placebo, N-acetylgalactosamine 4-sulfatase
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
7 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Novato, California
Source: ClinicalTrials.gov public record
Updated Dec 24, 2009 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation

NCT04452669
View directory record Official record
Conditions
COVID-19
Interventions
VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)
Drug
Lead sponsor
Aerogen Pharma Limited
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Not applicable Interventional

Benefit of CoQ-10 in Patients on Statins

NCT00997269
View directory record Official record
Conditions
Pain, Soreness, Weakness, Fatigue
Interventions
Co-enzyme Q-10, Placebo
Dietary Supplement
Lead sponsor
Stony Brook University
Other
Eligibility
21 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)

NCT05398445
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
50
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 15, 2026, 9:03 PM EDT
Terminated Phase 2 Interventional Results available

Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome

NCT01552681
View directory record Official record
Conditions
Primary Sjögren's Syndrome
Interventions
Baminercept, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Hartford, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 15, 2026, 9:03 PM EDT
Terminated Phase 2 Interventional Results available

Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.

NCT05142228
View directory record Official record
Conditions
Trigeminal Neuropathy
Interventions
Erenumab-Aooe, Placebo
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Intervention With Vitamin D and Omega-3 Supplements and Incident Heart Failure

NCT02271230
View directory record Official record
Conditions
Heart Failure
Interventions
Vitamin D and fish oil, Fish oil (EPA/DHA) alone, Vitamin D alone, Placebo
Drug · Dietary Supplement · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 15, 2026, 9:03 PM EDT
Terminated Phase 2 Interventional Results available

An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

NCT03391765
View directory record Official record
Conditions
Progressive Supranuclear Palsy (PSP)
Interventions
ABBV-8E12, Placebo solution for IV infusion on Day 15
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Mixed Working Memory Training on Subsequent Training Gains Among Older Adults

NCT05672771
View directory record Official record
Conditions
Cognitive Aging
Interventions
Different Mixed Condition (DM), Different Single Condition (DS), Same Task (ST) Practice Control, Non-WM Placebo Control (PC)
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
60 Years to 90 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors

NCT00415571
View directory record Official record
Conditions
Hypogonadism, Erectile Dysfunction
Interventions
Fispemifene (once daily for 8 weeks)
Drug
Lead sponsor
QuatRx Pharmaceuticals Company
Industry
Eligibility
20 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
14
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Oct 15, 2026, 9:03 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

NCT05379634
View directory record Official record
Conditions
Myositis
Interventions
Nipocalimab, Placebo, Glucocorticoids
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
19
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

NCT01358864
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
BI 201335, Pegylated Interferon-alpha (IFN), Ribavirin (RBV), Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
18
States / cities
North Little Rock, Arkansas • Englewood, Colorado • Palm Harbor, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Oct 15, 2026, 9:03 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Resveratrol and Cardiovascular Health in the Elderly

NCT01842399
View directory record Official record
Conditions
Vascular Resistance, Hypertension
Interventions
Resveratrol, Placebo
Dietary Supplement · Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
50 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Glutathione (an Antioxidant) and N-Acetylcysteine on Inflammation

NCT01550432
View directory record Official record
Conditions
Obesity, Hyperlipidemia, Insulin Resistance, Hypertension
Interventions
Glutathione, N-Acetylcysteine, Placebo
Dietary Supplement · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 15, 2026, 9:03 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

NCT06544616
View directory record Official record
Conditions
Alzheimer Disease
Interventions
JNJ-64042056, Placebo
Drug
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
55 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Irvine, California • Murrieta, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 15, 2026, 9:03 PM EDT